Advertisement
Canada markets closed

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7325
    +0.0028 (+0.38%)
     

  • CRUDE OIL

    83.80
    +0.99 (+1.20%)
     

  • Bitcoin CAD

    88,510.82
    +1,035.12 (+1.18%)
     

  • CMC Crypto 200

    1,399.98
    +17.41 (+1.26%)
     

  • GOLD FUTURES

    2,343.90
    +5.50 (+0.24%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,818.75
    +154.25 (+0.87%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6824
    +0.0005 (+0.07%)
     
MARKETS LIVE BLOG:

STOCKS SLIDE AFTER META'S REALITY CHECK, DOWNBEAT GDP

Caterpillar sinks 7% after earnings, management sees weakness in Europe, Asia-Pacific

Stocks in play: Fennec Pharmaceuticals Inc

Baystreet.ca

Today announced that the U.S. Food and Drug Administration has approved PEDMARK®, a sodium thiosulfate injection, to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors. This approval makes PEDMARK the first and only treatment approved by the FDA in this area of significant unmet medical need. Fennec Pharmaceuticals Inc shares T.FRX are trading up $0.94 at $10.88.

Read: